Notice Regarding the Disclosure of the Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 Exceeding 45 Days After the End of the Quarter

 

Notice Regarding the Disclosure of the Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 Exceeding 45 Days After the End of the Quarter

　

We hereby announce that the disclosure of the Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 is expected to exceed 45 days after the end of the quarter, as described below.

We sincerely apologize for any concern this may cause to our shareholders, investors, and all other related parties.

1.Reasons for the Disclosure of the Summary of Financial Results Exceeding 45 Days After the End of the Quarter

As announced in the "Notice Regarding the Postponement of the Announcement of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2027" dated August 7, 2026, we have postponed the announcement of financial results that was scheduled for August 7.

On August 6, the day before the scheduled announcement date, at 11:40 p.m., we received an initial notification from our accounting auditor that uncertainties arose regarding the accounting treatment at "Takara Bio USA, Inc.," our consolidated subsidiary. Subsequently, at 7:58 a.m. on August 7, we received notification from the accounting auditor that until the facts regarding the uncertainties are clarified and their content, including whether there is any impact, is determined, they would be unable to express a conclusion on the interim review of the quarterly consolidated financial statements.

In response to this situation, we determined that clarifying the facts should be our top priority, and we urgently postponed the announcement of financial results scheduled for August 7 and commenced an investigation into the facts.

As additional time is required to determine the facts, the disclosure of the Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 is expected to exceed 45 days after the end of the quarter.

2.Future Schedule

We are currently conducting an investigation into the facts with the involvement of legal experts and certified public accountants.

The rescheduled date for the announcement of financial results is currently undetermined, but we will promptly announce it once decided.

<Reference> Overview of Takara Bio USA, Inc.
- Location: San Jose, California, United States
- Representative: Andrew Farmer, President & CEO
- Capital: 83 thousand US dollars
- Number of employees: 244 (as of the fiscal year ending March 2026)
- Annual sales for the past three years (in thousands of US dollars)
 

	January-December 2023 (Fiscal year ending March 2024)	January-December 2024 (Fiscal year ending March 2025)	January-December 2025 (Fiscal year ending March 2026)
Net sales	120,786	113,029	107,217

 

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.